

Stephen L Hoffman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2730426/publications.pdf>

Version: 2024-02-01

265
papers

26,829
citations

8749

75
h-index

7736

150
g-index

275
all docs

275
docs citations

275
times ranked

17535
citing authors

#	ARTICLE	IF	CITATIONS
1	An efficient single-cell based method for linking human T cell phenotype to T cell receptor sequence and specificity. <i>European Journal of Immunology</i> , 2022, 52, 237-246.	1.6	3
2	Safety and efficacy of a three-dose regimen of <i>Plasmodium falciparum</i> sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial. <i>Lancet Infectious Diseases</i> , 2022, 22, 377-389.	4.6	44
3	Cryopreservation of <i>Anopheles stephensi</i> embryos. <i>Scientific Reports</i> , 2022, 12, 43.	1.6	3
4	Multi-Dose Priming Regimens of PfSPZ Vaccine: Safety and Efficacy against Controlled Human Malaria Infection in Equatoguinean Adults. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, 106, 1215-1226.	0.6	16
5	Diagnostic performance and comparison of ultrasensitive and conventional rapid diagnostic test, thick blood smear and quantitative PCR for detection of low-density <i>Plasmodium falciparum</i> infections during a controlled human malaria infection study in Equatorial Guinea. <i>Malaria Journal</i> , 2022, 21, 99.	0.8	9
6	Cryopreserved Sporozoites with and without the Glycolipid Adjuvant 7DW8-5 Protect in Prime-and-Trap Malaria Vaccination. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, 106, 1227-1236.	0.6	12
7	A First for Human Vaccinology: GMP Compliant Radiation Attenuation of <i>Plasmodium falciparum</i> Sporozoites for Production of a Vaccine Against Malaria. <i>Frontiers in Immunology</i> , 2022, 13, 851028.	2.2	4
8	Efficacy, T cell activation and antibody responses in accelerated <i>Plasmodium falciparum</i> sporozoite chemoprophylaxis vaccine regimens. <i>Npj Vaccines</i> , 2022, 7, .	2.9	3
9	Clonal evolution and TCR specificity of the human T _{FH} cell response to <i>Plasmodium falciparum</i> CSP. <i>Science Immunology</i> , 2022, 7, .	5.6	5
10	<i>Plasmodium falciparum</i> 7G8 challenge provides conservative prediction of efficacy of PfNF54-based PfSPZ Vaccine in Africa. <i>Nature Communications</i> , 2022, 13, .	5.8	8
11	Multidose Priming and Delayed Boosting Improve <i>Plasmodium falciparum</i> Sporozoite Vaccine Efficacy Against Heterologous <i>P. falciparum</i> Controlled Human Malaria Infection. <i>Clinical Infectious Diseases</i> , 2021, 73, e2424-e2435.	2.9	23
12	A Mosquito Pick-and-Place System for PfSPZ-Based Malaria Vaccine Production. <i>IEEE Transactions on Automation Science and Engineering</i> , 2021, 18, 299-310.	3.4	7
13	Immunogenicity and Protective Efficacy of Radiation-Attenuated and Chemo-Attenuated PfSPZ Vaccines in Equatoguinean Adults. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 104, 283-293.	0.6	49
14	Role of human Pegivirus infections in whole <i>Plasmodium falciparum</i> sporozoite vaccination and controlled human malaria infection in African volunteers. <i>Virology Journal</i> , 2021, 18, 28.	1.4	3
15	Expansion of Functional Myeloid-Derived Suppressor Cells in Controlled Human Malaria Infection. <i>Frontiers in Immunology</i> , 2021, 12, 625712.	2.2	10
16	Systems analysis and controlled malaria infection in Europeans and Africans elucidate naturally acquired immunity. <i>Nature Immunology</i> , 2021, 22, 654-665.	7.0	24
17	PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection. <i>PLoS Pathogens</i> , 2021, 17, e1009594.	2.1	34
18	Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial. <i>Nature Communications</i> , 2021, 12, 2518.	5.8	34

#	ARTICLE	IF	CITATIONS
19	Plasmodium falciparum LipB mutants display altered redox and carbon metabolism in asexual stages and cannot complete sporogony in Anopheles mosquitoes. International Journal for Parasitology, 2021, 51, 441-453.	1.3	9
20	Identification of the Glycan Binding Profile of Human and Rodent <i>Plasmodium</i> Sporozoites. ACS Infectious Diseases, 2021, 7, 2383-2389.	1.8	2
21	Exploratory analysis of the effect of helminth infection on the immunogenicity and efficacy of the asexual blood-stage malaria vaccine candidate GMZ2. PLoS Neglected Tropical Diseases, 2021, 15, e0009361.	1.3	13
22	Transient knockdown of Anopheles stephensi LRIM1 using RNAi increases Plasmodium falciparum sporozoite salivary gland infections. Malaria Journal, 2021, 20, 284.	0.8	6
23	Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity. Nature, 2021, 595, 289-294.	13.7	68
24	Incidence of Plasmodium falciparum malaria infection in 6-month to 45-year-olds on selected areas of Bioko Island, Equatorial Guinea. Malaria Journal, 2021, 20, 322.	0.8	3
25	Immunoprofiles associated with controlled human malaria infection and naturally acquired immunity identify a shared IgA pre-erythrocytic immunoproteome. Npj Vaccines, 2021, 6, 115.	2.9	2
26	Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial. Nature Medicine, 2021, 27, 1636-1645.	15.2	47
27	Nanotechnological immunoassay for rapid label-free analysis of candidate malaria vaccines. Nanoscale, 2021, 13, 2338-2349.	2.8	11
28	Knockout of Anopheles stephensi immune gene LRIM1 by CRISPR-Cas9 reveals its unexpected role in reproduction and vector competence. PLoS Pathogens, 2021, 17, e1009770.	2.1	8
29	Safety, Tolerability, and Immunogenicity of Plasmodium falciparum Sporozoite Vaccine Administered by Direct Venous Inoculation to Infants and Young Children: Findings From an Age De-escalation, Dose-Escalation, Double-blind, Randomized Controlled Study in Western Kenya. Clinical Infectious Diseases, 2020, 71, 1063-1071.	2.9	25
30	Serologic Markers of Previous Malaria Exposure and Functional Antibodies Inhibiting Parasite Growth Are Associated With Parasite Kinetics Following a Plasmodium falciparum Controlled Human Infection. Clinical Infectious Diseases, 2020, 70, 2544-2552.	2.9	33
31	Strains used in whole organism Plasmodium falciparum vaccine trials differ in genome structure, sequence, and immunogenic potential. Genome Medicine, 2020, 12, 6.	3.6	61
32	Ivermectin for causal malaria prophylaxis: a randomised controlled human infection trial. Tropical Medicine and International Health, 2020, 25, 380-386.	1.0	15
33	Activation of TCR V α 1+ and V α 1 β 2 γ 1 T Cells upon Controlled Infection with <i>Plasmodium falciparum</i> in Tanzanian Volunteers. Journal of Immunology, 2020, 204, 180-191.	0.4	14
34	Increase of Dose Associated With Decrease in Protection Against Controlled Human Malaria Infection by PfSPZ Vaccine in Tanzanian Adults. Clinical Infectious Diseases, 2020, 71, 2849-2857.	2.9	46
35	Quantification of Plasmodium knowlesi versus Plasmodium falciparum in the rhesus liver: implications for malaria vaccine studies in rhesus models. Malaria Journal, 2020, 19, 313.	0.8	7
36	Effect of immune regulatory pathways after immunization with GMZ2 malaria vaccine candidate in healthy lifelong malaria-exposed adults. Vaccine, 2020, 38, 4263-4272.	1.7	9

#	ARTICLE	IF	CITATIONS
37	Caregiver and community perceptions and experiences participating in an infant malaria prevention trial of PfSPZ Vaccine administered by direct venous inoculation: a qualitative study in Siaya County, western Kenya. <i>Malaria Journal</i> , 2020, 19, 226.	0.8	6
38	A double-blind, placebo-controlled phase 1/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	50
39	The Equatoguinean Malaria Vaccine Initiative: From the Launching of a Clinical Research Platform to Malaria Elimination Planning in Central West Africa. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 947-954.	0.6	13
40	Dose-Dependent Infectivity of Aseptic, Purified, Cryopreserved <i>Plasmodium falciparum</i> 7G8 Sporozoites in Malaria-Naive Adults. <i>Journal of Infectious Diseases</i> , 2019, 220, 1962-1966.	1.9	17
41	Controlled human malaria infection with <i>Plasmodium falciparum</i> demonstrates impact of naturally acquired immunity on virulence gene expression. <i>PLoS Pathogens</i> , 2019, 15, e1007906.	2.1	36
42	Transcriptome profiling reveals functional variation in <i>Plasmodium falciparum</i> parasites from controlled human malaria infection studies. <i>EBioMedicine</i> , 2019, 48, 442-452.	2.7	19
43	<i>Plasmodium vivax</i> chloroquine resistance links to <i>pv crt</i> transcription in a genetic cross. <i>Nature Communications</i> , 2019, 10, 4300.	5.8	35
44	Is Saglin a mosquito salivary gland receptor for <i>Plasmodium falciparum</i> ?. <i>Malaria Journal</i> , 2019, 18, 2.	0.8	14
45	Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2. <i>Clinical Infectious Diseases</i> , 2019, 69, 1377-1384.	2.9	53
46	Human challenge trials in vaccine development, Rockville, MD, USA, September 28–30, 2017. <i>Biologicals</i> , 2019, 61, 85-94.	0.5	29
47	Safety and Differential Antibody and T-Cell Responses to the <i>Plasmodium falciparum</i> Sporozoite Malaria Vaccine, PfSPZ Vaccine, by Age in Tanzanian Adults, Adolescents, Children, and Infants. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 100, 1433-1444.	0.6	61
48	Beyond Blood Smears: Qualification of <i>Plasmodium</i> 18S rRNA as a Biomarker for Controlled Human Malaria Infections. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 100, 1466-1476.	0.6	41
49	Clonal selection drives protective memory B cell responses in controlled human malaria infection. <i>Science Immunology</i> , 2018, 3, .	5.6	132
50	Induction of immunity following vaccination with a chemically attenuated malaria vaccine correlates with persistent antigenic stimulation. <i>Clinical and Translational Immunology</i> , 2018, 7, e1015.	1.7	5
51	A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. <i>Nature Medicine</i> , 2018, 24, 408-416.	15.2	235
52	A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein. <i>Nature Medicine</i> , 2018, 24, 401-407.	15.2	183
53	Rare PfCSP C-terminal antibodies induced by live sporozoite vaccination are ineffective against malaria infection. <i>Journal of Experimental Medicine</i> , 2018, 215, 63-75.	4.2	79
54	Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of <i>Plasmodium falciparum</i> Sporozoite Vaccine in Tanzanian Adults. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 99, 338-349.	0.6	114

#	ARTICLE	IF	CITATIONS
55	Artemisinin resistance phenotypes and K13 inheritance in a <i>Plasmodium falciparum</i> cross and <i>Aotus</i> model. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12513-12518.	3.3	46
56	Whole blood transcriptome changes following controlled human malaria infection in malaria pre-exposed volunteers correlate with parasite prepatent period. PLoS ONE, 2018, 13, e0199392.	1.1	18
57	Ruth Nussenzweig (1928–2018). Immunity, 2018, 48, 1061-1062.	6.6	0
58	Antihomotypic affinity maturation improves human B cell responses against a repetitive epitope. Science, 2018, 360, 1358-1362.	6.0	89
59	Impact of Sickle Cell Trait and Naturally Acquired Immunity on Uncomplicated Malaria after Controlled Human Malaria Infection in Adults in Gabon. American Journal of Tropical Medicine and Hygiene, 2018, 98, 508-515.	0.6	60
60	Advancing Global Health through Development and Clinical Trials Partnerships: A Randomized, Placebo-Controlled, Double-Blind Assessment of Safety, Tolerability, and Immunogenicity of PfSPZ Vaccine for Malaria in Healthy Equatoguinean Men. American Journal of Tropical Medicine and Hygiene, 2018, 98, 308-318.	0.6	55
61	Ruth Nussenzweig (1928–2018) Malaria Vaccine and Immunology Pioneer. American Journal of Tropical Medicine and Hygiene, 2018, 99, 253-254.	0.6	3
62	Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 2711-2716.	3.3	201
63	Safety and efficacy of PfSPZ Vaccine against <i>Plasmodium falciparum</i> via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infectious Diseases, The, 2017, 17, 498-509.	4.6	258
64	Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature, 2017, 542, 445-449.	13.7	332
65	Controlled Human Malaria Infection Leads to Long-Lasting Changes in Innate and Innate-like Lymphocyte Populations. Journal of Immunology, 2017, 199, 107-118.	0.4	45
66	DSM265 for <i>Plasmodium falciparum</i> chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection. Lancet Infectious Diseases, The, 2017, 17, 636-644.	4.6	83
67	Humoral protection against mosquito bite-transmitted <i>Plasmodium falciparum</i> infection in humanized mice. Npj Vaccines, 2017, 2, 27.	2.9	44
68	IFN- γ T Cells Are Required for the Induction of Sterile Immunity during Irradiated Sporozoite Vaccinations. Journal of Immunology, 2017, 199, 3781-3788.	0.4	80
69	Hexahydroquinolines are antimalarial candidates with potent blood-stage and transmission-blocking activity. Nature Microbiology, 2017, 2, 1403-1414.	5.9	47
70	Protection against <i>Plasmodium falciparum</i> malaria by PfSPZ Vaccine. JCI Insight, 2017, 2, e89154.	2.3	195
71	Changes in Serological Immunology Measures in UK and Kenyan Adults Post-controlled Human Malaria Infection. Frontiers in Microbiology, 2016, 7, 1604.	1.5	23
72	Mosquito bite immunization with radiation-attenuated <i>Plasmodium falciparum</i> sporozoites: safety, tolerability, protective efficacy and humoral immunogenicity. Malaria Journal, 2016, 15, 377.	0.8	29

#	ARTICLE	IF	CITATIONS
73	Mosquito Passage Dramatically Changes var Gene Expression in Controlled Human Plasmodium falciparum Infections. PLoS Pathogens, 2016, 12, e1005538.	2.1	54
74	Infectivity of Plasmodium falciparum in Malaria-Naive Individuals Is Related to Knob Expression and Cytoadherence of the Parasite. Infection and Immunity, 2016, 84, 2689-2696.	1.0	14
75	Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nature Medicine, 2016, 22, 614-623.	15.2	313
76	Chemically Attenuated Blood-Stage Plasmodium yoelii Parasites Induce Long-Lived and Strain-Transcending Protection. Infection and Immunity, 2016, 84, 2274-2288.	1.0	31
77	Alterations of blood coagulation in controlled human malaria infection. Malaria Journal, 2016, 15, 15.	0.8	26
78	Safety, Immunogenicity, and Protective Efficacy of Intradermal Immunization with Aseptic, Purified, Cryopreserved Plasmodium falciparum Sporozoites in Volunteers Under Chloroquine Prophylaxis: A Randomized Controlled Trial. American Journal of Tropical Medicine and Hygiene, 2016, 94, 663-673.	0.6	58
79	Optimizing Intradermal Administration of Cryopreserved Plasmodium falciparum Sporozoites in Controlled Human Malaria Infection. American Journal of Tropical Medicine and Hygiene, 2015, 93, 1274-1284.	0.6	23
80	Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naïve volunteers: effect of injection volume and dose on infectivity rates. Malaria Journal, 2015, 14, 306.	0.8	78
81	Discovery of Novel Plasmodium falciparum Pre-Erythrocytic Antigens for Vaccine Development. PLoS ONE, 2015, 10, e0136109.	1.1	36
82	Impact of Malaria Preexposure on Antiparasite Cellular and Humoral Immune Responses after Controlled Human Malaria Infection. Infection and Immunity, 2015, 83, 2185-2196.	1.0	40
83	Robust, reproducible, industrialized, standard membrane feeding assay for assessing the transmission blocking activity of vaccines and drugs against Plasmodium falciparum. Malaria Journal, 2015, 14, 150.	0.8	18
84	Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies. Malaria Journal, 2015, 14, 33.	0.8	39
85	Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres. Malaria Journal, 2015, 14, 117.	0.8	114
86	Development of cultured Plasmodium falciparum blood-stage malaria cell banks for early phase in vivo clinical trial assessment of anti-malaria drugs and vaccines. Malaria Journal, 2015, 14, 143.	0.8	38
87	Plasmodium falciparum Infection of Human Volunteers Activates Monocytes and CD16 + Dendritic Cells and Induces Upregulation of CD16 and CD1c Expression. Infection and Immunity, 2015, 83, 3732-3739.	1.0	31
88	Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines. Vaccine, 2015, 33, 7452-7461.	1.7	152
89	The march toward malaria vaccines. Vaccine, 2015, 33, D13-D23.	1.7	115
90	The March Toward Malaria Vaccines. American Journal of Preventive Medicine, 2015, 49, S319-S333.	1.6	124

#	ARTICLE	IF	CITATIONS
91	HIV Treatments Reduce Malaria Liver Stage Burden in a Non-Human Primate Model of Malaria Infection at Clinically Relevant Concentrations In Vivo. PLoS ONE, 2014, 9, e100138.	1.1	12
92	Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. Frontiers in Microbiology, 2014, 5, 686.	1.5	95
93	Idiopathic acute myocarditis during treatment for controlled human malaria infection: a case report. Malaria Journal, 2014, 13, 38.	0.8	28
94	Controlled Human Malaria Infection of Tanzanians by Intradermal Injection of Aseptic, Purified, Cryopreserved Plasmodium falciparum Sporozoites. American Journal of Tropical Medicine and Hygiene, 2014, 91, 471-480.	0.6	116
95	Two <i>Plasmodium</i> Cys family-related proteins have distinct and critical roles in liver stage development. FASEB Journal, 2014, 28, 2158-2170.	0.2	88
96	Type II Fatty Acid Biosynthesis Is Essential for Plasmodium falciparum Sporozoite Development in the Midgut of Anopheles Mosquitoes. Eukaryotic Cell, 2014, 13, 550-559.	3.4	116
97	BAFF and BAFF Receptor Levels Correlate with B Cell Subset Activation and Redistribution in Controlled Human Malaria Infection. Journal of Immunology, 2014, 192, 3719-3729.	0.4	67
98	A genetically attenuated malaria vaccine candidate based on P. falciparum b9/slarp gene-deficient sporozoites. ELife, 2014, 3, .	2.8	68
99	A Microscale Human Liver Platform that Supports the Hepatic Stages of Plasmodium falciparum and vivax. Cell Host and Microbe, 2013, 14, 104-115.	5.1	195
100	Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine. Science, 2013, 341, 1359-1365.	6.0	686
101	Comparative cost models of a liquid nitrogen vapor phase (LNVP) cold chain-distributed cryopreserved malaria vaccine vs. a conventional vaccine. Vaccine, 2013, 31, 380-386.	1.7	17
102	Controlled Human Malaria Infections by Intradermal Injection of Cryopreserved Plasmodium falciparum Sporozoites. American Journal of Tropical Medicine and Hygiene, 2013, 88, 5-13.	0.6	140
103	Plasmodium liver load following parenteral sporozoite administration in rodents. Vaccine, 2013, 31, 3410-3416.	1.7	28
104	Purnomo Projodipuro (April 11, 1934–May 10, 2013). American Journal of Tropical Medicine and Hygiene, 2013, 89, 202-204.	0.6	0
105	Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe. PLoS ONE, 2013, 8, e65960.	1.1	80
106	Successful Human Infection with P. falciparum Using Three Aseptic Anopheles stephensi Mosquitoes: A New Model for Controlled Human Malaria Infection. PLoS ONE, 2013, 8, e68969.	1.1	26
107	Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage <i>Plasmodium falciparum</i> DNA vaccine combined with escalating dose human GM-CSF DNA. Human Vaccines and Immunotherapeutics, 2012, 8, 1564-1584.	1.4	44
108	Assessing the adequacy of attenuation of genetically modified malaria parasite vaccine candidates. Vaccine, 2012, 30, 2662-2670.	1.7	61

#	ARTICLE	IF	CITATIONS
109	Delineation of Stage Specific Expression of Plasmodium falciparum EBA-175 by Biologically Functional Region II Monoclonal Antibodies. PLoS ONE, 2011, 6, e18393.	1.1	34
110	Immune Responses and Protection of Aotus Monkeys Immunized with Irradiated Plasmodium vivax Sporozoites. American Journal of Tropical Medicine and Hygiene, 2011, 84, 43-50.	0.6	13
111	Quantitative assessment of <i>Plasmodium falciparum</i> sexual development reveals potent transmission-blocking activity by methylene blue. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E1214-23.	3.3	293
112	Plasmodium yoelii-Infected A. stephensi Inefficiently Transmit Malaria Compared to Intravenous Route. PLoS ONE, 2010, 5, e8947.	1.1	23
113	Plasmodium falciparum Malaria Challenge by the Bite of Aseptic Anopheles stephensi Mosquitoes: Results of a Randomized Infectivity Trial. PLoS ONE, 2010, 5, e13490.	1.1	42
114	Establishment of an In Vitro Assay for Assessing the Effects of Drugs on the Liver Stages of Plasmodium vivax Malaria. PLoS ONE, 2010, 5, e14275.	1.1	67
115	Development of a metabolically active, non-replicating sporozoite vaccine to prevent <i>Plasmodium falciparum</i> malaria. Hum Vaccin, 2010, 6, 97-106.	2.4	258
116	Hark back: Passive immunotherapy for influenza and other serious infections. Critical Care Medicine, 2010, 38, e66-e73.	0.4	131
117	A Systems-Based Analysis of Plasmodium vivax Lifecycle Transcription from Human to Mosquito. PLoS Neglected Tropical Diseases, 2010, 4, e653.	1.3	96
118	Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and \pm DEC-CSP in non human primates. Vaccine, 2010, 28, 7256-7266.	1.7	119
119	Acquired Antibody Responses against Plasmodium vivax Infection Vary with Host Genotype for Duffy Antigen Receptor for Chemokines (DARC). PLoS ONE, 2010, 5, e11437.	1.1	23
120	The Potential Role of Vaccines in the Elimination of Falciparum Malaria and the Eventual Eradication of Malaria. Journal of Infectious Diseases, 2009, 200, 1646-1649.	1.9	57
121	Plasmodium: Mammalian codon optimization of malaria plasmid DNA vaccines enhances antibody responses but not T cell responses nor protective immunity. Experimental Parasitology, 2009, 122, 112-123.	0.5	15
122	The Effects of radiation on the safety and protective efficacy of an attenuated Plasmodium yoelii sporozoite malaria vaccine. Vaccine, 2009, 27, 3675-3680.	1.7	43
123	Comparative genomics of the neglected human malaria parasite Plasmodium vivax. Nature, 2008, 455, 757-763.	13.7	756
124	Plasmodium Falciparum : From Genomic Sequence to Vaccines and Drugs. Novartis Foundation Symposium, 2008, 229, 94-104.	1.2	2
125	TDR Thirty Years On: Taking Stock and Envisioning the Future for the Special Programme for Research and Training in Tropical Diseases. PLoS Neglected Tropical Diseases, 2008, 2, e314.	1.3	9
126	Gene Disruption of Plasmodium falciparum p52 Results in Attenuation of Malaria Liver Stage Development in Cultured Primary Human Hepatocytes. PLoS ONE, 2008, 3, e3549.	1.1	91

#	ARTICLE	IF	CITATIONS
127	Safety and Clinical Outcome of Experimental Challenge of Human Volunteers with <i>Plasmodium falciparum</i> "Infected Mosquitoes: An Update. <i>Journal of Infectious Diseases</i> , 2007, 196, 145-154.	1.9	118
128	Blood Products for Spanish Influenza: A Future H5N1 Treatment?. <i>Annals of Internal Medicine</i> , 2007, 146, 687.	2.0	3
129	Prevention and treatment of vivax malaria. <i>Current Infectious Disease Reports</i> , 2007, 9, 39-46.	1.3	41
130	Mefloquine treatment for uncomplicated <i>falciparum</i> malaria in young children 6-24 months of age in northern Ghana. <i>American Journal of Tropical Medicine and Hygiene</i> , 2007, 76, 224-31.	0.6	3
131	Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment?. <i>Annals of Internal Medicine</i> , 2006, 145, 599.	2.0	547
132	Boosting of DNA Vaccine-Elicited Gamma Interferon Responses in Humans by Exposure to Malaria Parasites. <i>Infection and Immunity</i> , 2005, 73, 2863-2872.	1.0	75
133	Comparative Analysis of Apicomplexa and Genomic Diversity in Eukaryotes. <i>Genome Research</i> , 2004, 14, 1686-1695.	2.4	172
134	Induction in Humans of CD8+ and CD4+ T Cell and Antibody Responses by Sequential Immunization with Malaria DNA and Recombinant Protein. <i>Journal of Immunology</i> , 2004, 172, 5561-5569.	0.4	97
135	Comparative immunopeptidomics of humans and their pathogens. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 13268-13272.	3.3	38
136	High-Throughput Generation of <i>P. falciparum</i> Functional Molecules by Recombinational Cloning. <i>Genome Research</i> , 2004, 14, 2076-2082.	2.4	58
137	Primaquine Therapy for Malaria. <i>Clinical Infectious Diseases</i> , 2004, 39, 1336-1345.	2.9	369
138	CpG Oligodeoxynucleotide and Montanide ISA 51 Adjuvant Combination Enhanced the Protective Efficacy of a Subunit Malaria Vaccine. <i>Infection and Immunity</i> , 2004, 72, 949-957.	1.0	87
139	Save the children. <i>Nature</i> , 2004, 430, 940-941.	13.7	20
140	Malaria transmission dynamics at a site in northern Ghana proposed for testing malaria vaccines. <i>Tropical Medicine and International Health</i> , 2004, 9, 164-170.	1.0	119
141	Seasonal profiles of malaria infection, anaemia, and bednet use among age groups and communities in northern Ghana. <i>Tropical Medicine and International Health</i> , 2003, 8, 793-802.	1.0	76
142	Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated <i>Plasmodium falciparum</i> sporozoite vaccine. <i>Journal of Experimental Biology</i> , 2003, 206, 3803-3808.	0.8	232
143	A Randomized, Double-blind, Placebo-controlled, Dose-ranging Trial of Tafenoquine for Weekly Prophylaxis against <i>Plasmodium falciparum</i> . <i>Clinical Infectious Diseases</i> , 2003, 36, 541-549.	2.9	79
144	Primaquine for Prevention of Malaria in Travelers. <i>Clinical Infectious Diseases</i> , 2003, 37, 1659-1667.	2.9	109

#	ARTICLE	IF	CITATIONS
145	PfSPATR, a Plasmodium falciparum Protein Containing an Altered Thrombospondin Type I Repeat Domain Is Expressed at Several Stages of the Parasite Life Cycle and Is the Target of Inhibitory Antibodies. <i>Journal of Biological Chemistry</i> , 2003, 278, 25977-25981.	1.6	52
146	Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 9952-9957.	3.3	227
147	Successful Induction of CD8 T Cell-Dependent Protection Against Malaria by Sequential Immunization with DNA and Recombinant Poxvirus of Neonatal Mice Born to Immune Mothers. <i>Journal of Immunology</i> , 2003, 171, 3148-3153.	0.4	26
148	Atovaquone/Proguanil Therapy for Plasmodium falciparum and Plasmodium vivax Malaria in Indonesians Who Lack Clinical Immunity. <i>Clinical Infectious Diseases</i> , 2002, 35, e92-e95.	2.9	33
149	Persistence of Protective Immunity to Malaria Induced by DNA Priming and Poxvirus Boosting: Characterization of Effector and Memory CD8+ T-Cell Populations. <i>Infection and Immunity</i> , 2002, 70, 3493-3499.	1.0	38
150	Protection of Rhesus Macaques against Lethal Plasmodium knowlesi Malaria by a Heterologous DNA Priming and Poxvirus Boosting Immunization Regimen. <i>Infection and Immunity</i> , 2002, 70, 4329-4335.	1.0	75
151	Randomized, Placebo-Controlled Trial of Atovaquone/Proguanil for the Prevention of Plasmodium falciparum or Plasmodium vivax Malaria among Migrants to Papua, Indonesia. <i>Clinical Infectious Diseases</i> , 2002, 35, 825-833.	2.9	82
152	Protection of Humans against Malaria by Immunization with Radiation-Attenuated Plasmodium falciparum Sporozoites. <i>Journal of Infectious Diseases</i> , 2002, 185, 1155-1164.	1.9	652
153	The Genome Sequence of the Malaria Mosquito Anopheles gambiae. <i>Science</i> , 2002, 298, 129-149.	6.0	1,859
154	Safety, Tolerability, and Lack of Antibody Responses After Administration of a PfCSP DNA Malaria Vaccine via Needle or Needle-Free Jet Injection, and Comparison of Intramuscular and Combination Intramuscular/Intradermal Routes. <i>Human Gene Therapy</i> , 2002, 13, 1551-1560.	1.4	102
155	PARASITOLOGY: Enhanced: Malaria—from Infants to Genomics to Vaccines. <i>Science</i> , 2002, 297, 345-347.	6.0	24
156	Laser capture microdissection and molecular analysis of Plasmodium yoelii liver-stage parasites. <i>Molecular and Biochemical Parasitology</i> , 2002, 119, 285-289.	0.5	21
157	A multilateral effort to develop DNA vaccines against falciparum malaria. <i>Trends in Parasitology</i> , 2002, 18, 129-135.	1.5	41
158	A DNA vaccine encoding the 42 kDa C-terminus of merozoite surface protein 1 of Plasmodium falciparum induces antibody, interferon- γ and cytotoxic T cell responses in rhesus monkeys: immuno-stimulatory effects of granulocyte macrophage-colony stimulating factor. <i>Immunology Letters</i> , 2002, 81, 13-24.	1.1	43
159	Sequence of Plasmodium falciparum chromosomes 2, 10, 11 and 14. <i>Nature</i> , 2002, 419, 531-534.	13.7	167
160	Genome sequence of the human malaria parasite Plasmodium falciparum. <i>Nature</i> , 2002, 419, 498-511.	13.7	3,881
161	Genome sequence and comparative analysis of the model rodent malaria parasite Plasmodium yoelii yoelii. <i>Nature</i> , 2002, 419, 512-519.	13.7	666
162	Plasmodium, human and Anopheles genomics and malaria. <i>Nature</i> , 2002, 415, 702-709.	13.7	126

#	ARTICLE	IF	CITATIONS
163	Cures for the Third World's problems. <i>EMBO Reports</i> , 2002, 3, 806-812.	2.0	25
164	Assessing the Parasight-F test in northeastern Papua, Indonesia, an area of mixed <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> transmission.. <i>American Journal of Tropical Medicine and Hygiene</i> , 2002, 66, 649-652.	0.6	9
165	Anemia in parasite- and recombinant protein-immunized aotus monkeys infected with <i>Plasmodium falciparum</i> .. <i>American Journal of Tropical Medicine and Hygiene</i> , 2002, 66, 672-679.	0.6	34
166	Presidential address: The American Society of Tropical Medicine and Hygiene in the last half century: from apparent anachronism to international leader and innovator.. <i>American Journal of Tropical Medicine and Hygiene</i> , 2002, 67, 1-7.	0.6	1
167	Determining liver stage parasite burden by real time quantitative PCR as a method for evaluating pre-erythrocytic malaria vaccine efficacy. <i>Molecular and Biochemical Parasitology</i> , 2001, 118, 233-245.	0.5	71
168	ELISPOT assay for detection of peptide specific Interferon- γ secreting cells in rhesus macaques. <i>Journal of Immunological Methods</i> , 2001, 247, 49-60.	0.6	47
169	Expression of the chemokine MIG is a sensitive and predictive marker for antigen-specific, genetically restricted IFN- γ production and IFN- γ -secreting cells. <i>Journal of Immunological Methods</i> , 2001, 257, 55-69.	0.6	37
170	DNA-based vaccines against malaria: status and promise of the Multi-Stage Malaria DNA Vaccine Operation. <i>International Journal for Parasitology</i> , 2001, 31, 753-762.	1.3	100
171	Expression, Extracellular Secretion, and Immunogenicity of the <i>Plasmodium falciparum</i> Sporozoite Surface Protein 2 in <i>Salmonella</i> Vaccine Strains. <i>Infection and Immunity</i> , 2001, 69, 1192-1198.	1.0	24
172	Immunogenicity and Protective Efficacy of a <i>Plasmodium yoelii</i> Hsp60 DNA Vaccine in BALB/c Mice. <i>Infection and Immunity</i> , 2001, 69, 3897-3905.	1.0	23
173	Interleukin-12- and Gamma Interferon-Dependent Protection against Malaria Conferred by CpG Oligodeoxynucleotide in Mice. <i>Infection and Immunity</i> , 2001, 69, 1643-1649.	1.0	144
174	HLA-A*01-Restricted Cytotoxic T-Lymphocyte Epitope from the <i>Plasmodium falciparum</i> Circumsporozoite Protein. <i>Infection and Immunity</i> , 2001, 69, 2766-2771.	1.0	10
175	Codon Optimization of Gene Fragments Encoding <i>Plasmodium falciparum</i> Merzoite Proteins Enhances DNA Vaccine Protein Expression and Immunogenicity in Mice. <i>Infection and Immunity</i> , 2001, 69, 7250-7253.	1.0	110
176	Multistage Multiantigen Heterologous Prime Boost Vaccine for <i>Plasmodium knowlesi</i> Malaria Provides Partial Protection in Rhesus Macaques. <i>Infection and Immunity</i> , 2001, 69, 5565-5572.	1.0	80
177	Immunogenicity of Well-Characterized Synthetic <i>Plasmodium falciparum</i> Multiple Antigen Peptide Conjugates. <i>Infection and Immunity</i> , 2001, 69, 4884-4890.	1.0	29
178	Microbial Disease in Humans: A Genomic Perspective. <i>Molecular Diagnosis and Therapy</i> , 2001, 6, 243-252.	1.2	19
179	HLA degenerate T-cell epitopes from <i>Plasmodium falciparum</i> liver stage-specific antigen 1 (LSA-1) are highly conserved in isolates from geographically distinct areas. <i>Parasite Immunology</i> , 2000, 22, 469-473.	0.7	5
180	Malaria vaccinesâ€“targeting infected hepatocytes. <i>Nature Medicine</i> , 2000, 6, 1218-1219.	15.2	56

#	ARTICLE	IF	CITATIONS
181	Please don't downgrade the sequencers' role. Nature, 2000, 406, 121-122.	13.7	31
182	A Subdominant CD8 + Cytotoxic T Lymphocyte (CTL) Epitope from the Plasmodium yoelii Circumsporozoite Protein Induces CTLs That Eliminate Infected Hepatocytes from Culture. Infection and Immunity, 2000, 68, 3403-3411.	1.0	38
183	Improving Protective Immunity Induced by DNA-Based Immunization: Priming with Antigen and GM-CSF-Encoding Plasmid DNA and Boosting with Antigen-Expressing Recombinant Poxvirus. Journal of Immunology, 2000, 164, 5905-5912.	0.4	122
184	Antibodies against the Plasmodium falciparum Receptor Binding Domain of EBA-175 Block Invasion Pathways That Do Not Involve Sialic Acids. Infection and Immunity, 2000, 68, 1964-1966.	1.0	82
185	The Complexity of Protective Immunity Against Liver-Stage Malaria. Journal of Immunology, 2000, 165, 1453-1462.	0.4	313
186	Recombinant Attenuated <i>Toxoplasma gondii</i> Expressing the <i>Plasmodium yoelii</i> Circumsporozoite Protein Provides Highly Effective Priming for CD8+ T Cell-Dependent Protective Immunity Against Malaria. Journal of Immunology, 2000, 165, 2084-2092.	0.4	46
187	HLA-DR-Promiscuous T Cell Epitopes from <i>Plasmodium falciparum</i> Pre-Erythrocytic-Stage Antigens Restricted by Multiple HLA Class II Alleles. Journal of Immunology, 2000, 165, 1123-1137.	0.4	134
188	Plasmid Vaccine Expressing Granulocyte-Macrophage Colony-Stimulating Factor Attracts Infiltrates Including Immature Dendritic Cells into Injected Muscles. Journal of Immunology, 2000, 165, 3772-3781.	0.4	101
189	Plasmid DNA Malaria Vaccine: The Potential for Genomic Integration after Intramuscular Injection. Human Gene Therapy, 1999, 10, 759-768.	1.4	139
190	A shotgun optical map of the entire Plasmodium falciparum genome. Nature Genetics, 1999, 23, 309-313.	9.4	78
191	Plasmodium yoelii: Cloning and Characterization of the Gene Encoding for the Mitochondrial Heat Shock Protein 60. Experimental Parasitology, 1999, 93, 181-190.	0.5	20
192	TRAVEL VACCINES*. Infectious Disease Clinics of North America, 1999, 13, 149-167.	1.9	5
193	Plasmid DNA Malaria Vaccine: Tissue Distribution and Safety Studies in Mice and Rabbits. Human Gene Therapy, 1999, 10, 741-758.	1.4	106
194	CD4 ⁺ T-Cell- and Gamma Interferon-Dependent Protection against Murine Malaria by Immunization with Linear Synthetic Peptides from a <i>Plasmodium yoelii</i> 17-Kilodalton Hepatocyte Erythrocyte Protein. Infection and Immunity, 1999, 67, 5604-5614.	1.0	50
195	Optical Mapping of <i>Plasmodium falciparum</i> Chromosome 2. Genome Research, 1999, 9, 175-181.	2.4	30
196	Research toward vaccines against malaria. Nature Medicine, 1998, 4, 520-524.	15.2	94
197	From genomics to vaccines: Malaria as a model system. Nature Medicine, 1998, 4, 1351-1353.	15.2	67
198	The optimization of helper T lymphocyte (HTL) function in vaccine development. Immunologic Research, 1998, 18, 79-92.	1.3	115

#	ARTICLE	IF	CITATIONS
199	Induction of Antigen-Specific Cytotoxic T Lymphocytes in Humans by a Malaria DNA Vaccine. , 1998, 282, 476-480.		761
200	Chromosome Sequence of the Human Malaria Parasite Plasmodium falciparum. , 1998, 282, 1126-1132.		419
201	Phase I/IIa Safety, Immunogenicity, and Efficacy Trial of NYVAC-Pf7, a Pox-Vectored, Multiantigen, Multistage Vaccine Candidate for Plasmodium falciparum Malaria. Journal of Infectious Diseases, 1998, 177, 1664-1673.	1.9	224
202	Sequencing the genome of Plasmodium falciparum. Current Opinion in Infectious Diseases, 1998, 11, 531-534.	1.3	4
203	The Malaria Genome Sequencing Project. Expert Reviews in Molecular Medicine, 1998, 1, 1-9.	1.6	8
204	Protection of Mice against Plasmodium yoelii Sporozoite Challenge with P. yoelii Merozoite Surface Protein 1 DNA Vaccines. Infection and Immunity, 1998, 66, 3457-3461.	1.0	40
205	Simultaneous Induction of Multiple Antigen-Specific Cytotoxic T Lymphocytes in Nonhuman Primates by Immunization with a Mixture of Four Plasmodium falciparum DNA Plasmids. Infection and Immunity, 1998, 66, 4193-4202.	1.0	62
206	Simultaneous Induction of Multiple Antigen-Specific Cytotoxic T Lymphocytes in Nonhuman Primates by Immunization with a Mixture of Four Plasmodium falciparum DNA Plasmids. Infection and Immunity, 1998, 66, 4193-4202.	1.0	20
207	Do DNA Vaccines Induce Autoimmune Disease?. Human Gene Therapy, 1997, 8, 293-300.	1.4	162
208	Lymphocyte Response to Tetanus Toxoid among Indonesian Men Immunized with Tetanus-Diphtheria during Extended Chloroquine or Primaquine Prophylaxis. Journal of Infectious Diseases, 1997, 176, 1644-1648.	1.9	12
209	Clinical Manifestations of Plasmodium falciparum Malaria Experimentally Induced by Mosquito Challenge. Journal of Infectious Diseases, 1997, 175, 915-920.	1.9	108
210	Degenerate Cytotoxic T Cell Epitopes from P. falciparum Restricted by Multiple HLA-A and HLA-B Supertype Alleles. Immunity, 1997, 7, 97-112.	6.6	190
211	Experimental Challenge of Volunteers with Malaria. Annals of Internal Medicine, 1997, 127, 233.	2.0	18
212	Funding for malaria genome sequencing. Nature, 1997, 387, 647-647.	13.7	432
213	Toward clinical trials of DNA vaccines against malaria. Immunology and Cell Biology, 1997, 75, 376-381.	1.0	25
214	Cytotoxic T lymphocyte (CTL) adherence assay (CAA): a non-radioactive assay for murine CTL recognition of peptide-MHC class I complexes. Journal of Immunological Methods, 1997, 201, 1-10.	0.6	4
215	Autologous lymphoblastoid cell lines stably transfected with Plasmodium falciparum circumsporozoite protein as targets in cytotoxic T-lymphocyte assays. Immunology Letters, 1997, 55, 183-187.	1.1	1
216	Cytotoxic T cell reactivity and HLA-B35 binding of the variant Plasmodium falciparum circumsporozoite protein CD8+ CTL epitope in naturally exposed Kenyan adults. European Journal of Immunology, 1997, 27, 1952-1957.	1.6	29

#	ARTICLE	IF	CITATIONS
217	Plasmodium falciparum Gametocytemia in Kenyan Children: Associations among Age, Intensity of Exposure to Transmission, and Prevalence and Density of Subsequent Gametocytemia. American Journal of Tropical Medicine and Hygiene, 1997, 56, 133-136.	0.6	7
218	Malaria in a Nonimmune Population after Extended Chloroquine or Primaquine Prophylaxis. American Journal of Tropical Medicine and Hygiene, 1997, 56, 137-140.	0.6	21
219	Diagnosis of Resistance to Chloroquine by Plasmodium vivax: Timing of Recurrence and Whole Blood Chloroquine Levels. American Journal of Tropical Medicine and Hygiene, 1997, 56, 621-626.	0.6	153
220	Assessment of Age-Dependent Immunity to Malaria in Transmigrants. American Journal of Tropical Medicine and Hygiene, 1997, 56, 647-649.	0.6	10
221	Progress in prevention and treatment of malaria. Current Opinion in Infectious Diseases, 1996, 9, 319-329.	1.3	3
222	DNA vaccination against malaria. Advanced Drug Delivery Reviews, 1996, 21, 49-61.	6.6	4
223	Class I HLA-restricted cytotoxic T lymphocyte responses against malaria-elucidation on the basis of HLA peptide binding motifs. Immunologic Research, 1996, 15, 280-305.	1.3	20
224	Protective efficacy against malaria of a combination sporozoite and erythrocytic stage vaccine. Immunology Letters, 1996, 53, 83-93.	1.1	9
225	DNA Vaccines against Malaria: Immunogenicity and Protection in a Rodent Model. Journal of Pharmaceutical Sciences, 1996, 85, 1294-1300.	1.6	34
226	Identification and Characterization of the Protective Gene of homolog of Exported Protein 1. Journal of Biological Chemistry, 1996, 271, 17861-17868.	1.6	81
227	Artemether in Severe Malaria " Still Too Many Deaths. New England Journal of Medicine, 1996, 335, 124-126.	13.9	48
228	Malaria Epitopes Expressed on the surface of Recombinant Tobacco Mosaic Virus. Nature Biotechnology, 1995, 13, 53-57.	9.4	221
229	Treatment of Chloroquine-Resistant Plasmodium vivax with Chloroquine and Primaquine or Halofantrine. Journal of Infectious Diseases, 1995, 171, 1678-1682.	1.9	106
230	Polymerase Chain Reaction Amplification from Plasmodium falciparum on Dried Blood Spots. American Journal of Tropical Medicine and Hygiene, 1995, 52, 344-346.	0.6	33
231	Plasmodium Vivax: Freeze-Fracture Studies on the Ultrastructure of the Sporozoites within the Salivary Gland of the Mosquito Anopheles Stephensi. American Journal of Tropical Medicine and Hygiene, 1995, 52, 443-449.	0.6	3
232	Primaquine for Prophylaxis against Malaria among Nonimmune Transmigrants in Irian Jaya, Indonesia. American Journal of Tropical Medicine and Hygiene, 1995, 52, 479-484.	0.6	59
233	Inducing protective immune responses against the sporozoite and liver stages of Plasmodium. Immunology Letters, 1994, 41, 89-94.	1.1	10
234	Induction of murine cytotoxic T lymphocytes against Plasmodium falciparum sporozoite surface protein 2. European Journal of Immunology, 1994, 24, 1487-1495.	1.6	20

#	ARTICLE	IF	CITATIONS
235	Plasmodium falciparum Incidence Relative to Entomologic Inoculation Rates at a Site Proposed for Testing Malaria Vaccines in Western Kenya. American Journal of Tropical Medicine and Hygiene, 1994, 50, 529-536.	0.6	209
236	Safety, Immunogenicity, and Efficacy of a Malaria Sporozoite Vaccine Administered with Monophosphoryl Lipid A, Cell Wall Skeleton of Mycobacteria, and Squalane as Adjuvant. American Journal of Tropical Medicine and Hygiene, 1994, 51, 603-612.	0.6	63
237	Acridine Orange Diagnosis of Plasmodium falciparum: Evaluation after Experimental Infection. American Journal of Tropical Medicine and Hygiene, 1994, 51, 613-616.	0.6	19
238	History of Malaria in the United States Naval Forces at War: World War I Through the Vietnam Conflict. Clinical Infectious Diseases, 1993, 16, 320-329.	2.9	48
239	Humoral Immune Responses in Volunteers Immunized with Irradiated Plasmodium falciparum Sporozoites. American Journal of Tropical Medicine and Hygiene, 1993, 49, 166-173.	0.6	118
240	Immunology and pathogenic mechanisms of malaria. Current Opinion in Infectious Diseases, 1992, 5, 310-318.	1.3	0
241	A monoclonal antibody directed against the sporozoite stage of Plasmodium vivax binds to liver parenchymal cells. Immunology Letters, 1992, 33, 289-294.	1.1	3
242	Characterization of the gene encoding sporozoite surface protein 2, a protective Plasmodium yoelii sporozoite antigen. Molecular and Biochemical Parasitology, 1992, 53, 45-51.	0.5	74
243	Low Immunogenicity of a Plasmodium vivax Circumsporozoite Protein Epitope Bound by a Protective Monoclonal Antibody. American Journal of Tropical Medicine and Hygiene, 1992, 47, 837-843.	0.6	13
244	Immunology, pathophysiology, and treatment of malaria. Current Opinion in Infectious Diseases, 1991, 4, 265-272.	1.3	1
245	Acridine Orange Detection of Plasmodium Falciparum Malaria: Relationship between Sensitivity and Optical Configuration. American Journal of Tropical Medicine and Hygiene, 1991, 44, 402-405.	0.6	10
246	Resistance to Chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. American Journal of Tropical Medicine and Hygiene, 1991, 44, 547-552.	0.6	197
247	Irradiated sporozoite vaccine induces cytotoxic T lymphocytes that recognize malaria antigens on the surface of infected hepatocytes. Immunology Letters, 1990, 25, 33-38.	1.1	36
248	Cellular mechanisms of nonspecific immunity to intracellular infection: Cytokine-induced synthesis of toxic nitrogen oxides from L-arginine by macrophages and hepatocytes. Immunology Letters, 1990, 25, 15-19.	1.1	178
249	In Reply: Malaria Vaccines. Science, 1990, 248, 422-422.	6.0	1
250	Plasmodium Falciparum-Infected Anopheles Stephensi Inconsistently Transmit Malaria to Humans. American Journal of Tropical Medicine and Hygiene, 1990, 43, 441-445.	0.6	79
251	Malaria Vaccines. Science, 1990, 248, 422-422.	6.0	0
252	Cultivation of the exoerythrocytic stage of Plasmodium berghei in primary cultures of mouse hepatocytes and continuous mouse cell lines. In Vitro Cellular & Developmental Biology, 1989, 25, 857-862.	1.0	11

#	ARTICLE	IF	CITATIONS
253	Immunization of Saimiri Sciureus Boliviensis with Recombinant Vaccines Based on the Circumsporozoite Protein of Plasmodium Vivax. American Journal of Tropical Medicine and Hygiene, 1989, 40, 455-464.	0.6	52
254	TREATMENT OF SEVERE TYPHOID FEVER IN CHILDREN WITH HIGH DOSE DEXAMETHASONE. Pediatric Infectious Disease Journal, 1988, 7, 598-599.	1.1	40
255	Immune Response of Humans to the Circumsporozoite Protein of Plasmodium falciparum: Limited T Cell Response to the Immunodominant Central Repeat Region. American Journal of Tropical Medicine and Hygiene, 1988, 39, 232-235.	0.6	13
256	Plasmodium falciparum: Sporozoite boosting of immunity due to a T-cell epitope on a sporozoite vaccine. Experimental Parasitology, 1987, 64, 64-70.	0.5	27
257	THE WIDAL SLIDE AGGLUTINATION TEST, A VALUABLE RAPID DIAGNOSTIC TEST IN TYPHOID FEVER PATIENTS AT THE INFECTIOUS DISEASES HOSPITAL OF JAKARTA. American Journal of Epidemiology, 1986, 123, 869-875.	1.6	41
258	Immunity to Malaria and Naturally Acquired Antibodies to the Circumsporozoite Protein of Plasmodium falciparum. New England Journal of Medicine, 1986, 315, 601-606.	13.9	119
259	Malaria Transmitted to Humans by Mosquitoes Infected from Cultured Plasmodium falciparum. American Journal of Tropical Medicine and Hygiene, 1986, 35, 66-68.	0.6	133
260	Bone Marrow Aspirate Culture Superior to Streptokinase Clot Culture and 8 ml 1:10 Blood-to-Broth Ratio Blood Culture for Diagnosis of Typhoid Fever. American Journal of Tropical Medicine and Hygiene, 1986, 35, 836-839.	0.6	55
261	In Vitro Growth Inhibition of Plasmodium Falciparum by Sera from Tropical Splenomegaly Syndrome Patients. American Journal of Tropical Medicine and Hygiene, 1986, 35, 708-710.	0.6	0
262	Reduction of Mortality in Chloramphenicol-Treated Severe Typhoid Fever by High-Dose Dexamethasone. New England Journal of Medicine, 1984, 310, 82-88.	13.9	308
263	Reduction of Suppressor T Lymphocytes in the Tropical Splenomegaly Syndrome. New England Journal of Medicine, 1984, 310, 337-341.	13.9	54
264	Antigen-Specific Suppressor T Lymphocytes in Human Lymphatic Filariasis. New England Journal of Medicine, 1982, 307, 144-148.	13.9	117
265	Intestinal Parasites in Indochinese Immigrants *. American Journal of Tropical Medicine and Hygiene, 1981, 30, 340-343.	0.6	34